PRPH Stock Overview
Develops and commercializes novel drugs, dietary supplements, and compounds in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
ProPhase Labs, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.18 |
52 Week High | US$7.59 |
52 Week Low | US$4.03 |
Beta | -0.17 |
11 Month Change | -18.83% |
3 Month Change | -38.98% |
1 Year Change | -42.42% |
33 Year Change | -28.42% |
5 Year Change | 106.93% |
Change since IPO | 736.00% |
Recent News & Updates
Recent updates
Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?
Mar 04ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry
Jan 09ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate
Sep 21Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt
Aug 11We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease
Apr 07ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly
Jan 24ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential
Oct 13ProPhase Labs Q2 2022 Earnings Preview
Aug 10We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt
Jul 26ProPhase Labs to license two investigational cancer compounds from Global BioLife
Jul 21ProPhase Labs: A Stellar Quarter And Another Special Dividend
May 16ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 08ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely
Mar 23Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt
Nov 30As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit
Oct 20Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Jul 22ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants
Jun 28Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More
May 14ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing
May 06A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Apr 12ProPhase Labs opens Covid testing facility in New York
Jan 29Shareholder Returns
PRPH | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -4.8% | -0.3% | 0.07% |
1Y | -42.4% | 17.1% | 20.7% |
Return vs Industry: PRPH underperformed the US Pharmaceuticals industry which returned 17.1% over the past year.
Return vs Market: PRPH underperformed the US Market which returned 20.7% over the past year.
Price Volatility
PRPH volatility | |
---|---|
PRPH Average Weekly Movement | 11.4% |
Pharmaceuticals Industry Average Movement | 9.9% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: PRPH's share price has been volatile over the past 3 months.
Volatility Over Time: PRPH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 113 | Ted Karkus | www.prophaselabs.com |
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
ProPhase Labs, Inc. Fundamentals Summary
PRPH fundamental statistics | |
---|---|
Market cap | US$79.75m |
Earnings (TTM) | -US$23.60m |
Revenue (TTM) | US$28.72m |
2.8x
P/S Ratio-3.4x
P/E RatioIs PRPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PRPH income statement (TTM) | |
---|---|
Revenue | US$28.72m |
Cost of Revenue | US$23.43m |
Gross Profit | US$5.29m |
Other Expenses | US$28.88m |
Earnings | -US$23.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.24 |
Gross Margin | 18.41% |
Net Profit Margin | -82.18% |
Debt/Equity Ratio | 28.3% |
How did PRPH perform over the long term?
See historical performance and comparison